Clinical trial
Study of Satraplatin (JM-216) in Combination With Docetaxel
NCT00125411 · Agennix, Industry · Terminated
Key facts
| NCT number | NCT00125411 |
|---|---|
| Title | Study of Satraplatin (JM-216) in Combination With Docetaxel |
| Official title | Phase I Study of the Oral Platinum Agent Satraplatin (JM-216) in Combination With Docetaxel in Treatment of Advanced Malignancies |
| Lead sponsor | Agennix, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | satraplatin and docetaxel |
| Enrollment | 28 |
| Start date | Mar 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Aug 1, 2005 |
| Last update posted | Mar 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: